GenePlanet, one of the leading genetics companies in Europe and present in more than 30 countries worldwide, is specialised in genetic testing and related advanced molecular techniques. It is recognised for offering personalised DNA analyses.
By being R&D oriented, GenePlanet constantly strives for new discoveries that enable it to provide its clients with the latest and best products developed from its in-house research and development.
The company was established in 2008 in Slovenia by Marko Bitenc, a Silicon Valley Singularity University alumnum, and closed earlier this year an EUR 10m equity deal in exchange for a qualified minority stake with Zurich-based JF Investments AG. The Swiss funds will be used to develop its Health Intelligence platform and for the companys expansion plan to Asia.
Health Intelligence will integrate biological data (genetic and blood tests) with information from smart devices, wearables and sport tracking services. By setting personal goals and challenges, the user will be able to monitor their progress in specific areas such as nutrition & diet, training & sports, skincare and mental well-being to facilitate long-term behavioural changes that lead to better overall health.
Through its successful flagship brand NutriFit – with an overall satisfaction rate of 4,62 (out of 5) – GenePlanet has in the meantime emerged to become one of the most important players in the field of Nutrigenomics where it has developed a wide-ranged client base across different industries – healthcare, wellness and the insurance sector. With a simple saliva-based test, individuals can discover how their genes affect their nutrition, physical activity and lifestyle.
Moreover, GenePlanet is also strongly committed to diagnostic genetic testing and research. The company offers a non-invasive prenatal testing based on cell-free foetal DNA for detection of Down syndrome and other chromosomal abnormalities (NIPT); accurate test for more than 600 genetic disorders for future parents (Carrier Screen); a test for 87 genetic disorders & 32 medications (Newborn Screen) and Cancer Screen for hereditary cancer risk assessment.